Le Lézard
Classified in: Health, Science and technology
Subjects: Product/Service, Award

DataLink's Evoke360 Population Health Solution Receives NCQA Health Plan Measure Certification? for HEDIS® Measures 2020


DataLink Software (DataLink), a leading solution to enhance interoperability, reduce costs, improve quality scores and ensure risk adjustment accuracy, has achieved the National Committee for Quality Assurance (NCQA) certification for the Healthcare Effectiveness Data and Information Set (HEDIS®) Health Plan 2020 for all measures. NCQA's HEDIS Health Plan Measure Certification? is precise, automated testing that verifies compliance with HEDIS and further validates the Evoke360 population health solution, formerly CareBook, to offer real-time data aggregation that assists in quality improvement initiatives.

"Our participation in NCQA's Health Plan Measure Certification program ensures the highest level of quality and demonstrates to health plans the integrity of our solution," says Kevin Steele, chief executive officer, DataLink. "We provide a best-in-class technology approach that minimizes up-front investment while delivering premier analytics and value-based intelligence to reduce costs, and improve quality and care delivery for patients, providers and health plans."

Evoke360 is a clinical, operational and social determinant data platform built from a mindset of providing a holistic view of the patient with true data transparency, comprehensive insights related to chronic conditions, pharmacy, laboratory tests, gaps in care, social needs, quality and risk adjustment metrics. Evoke360 optimizes quality, reduces administrative burden, enables value-based care and enhances financial performance and communication with visibility into all health plan operations in one point-of-care solution.

Over 90 percent of America's health plans use the NCQA certification for HEDIS measures to evaluate and improve overall performance.

Steele adds, "This HEDIS certification demonstrates DataLink's commitment to empowering better health by enabling payers, providers and care partners with real-time data aggregation, EHR connectivity and dynamic dashboards and reporting. Our solution reduces costs, improves quality scores and simplifies healthcare navigation. This serves as testimony to our ability to support care delivery, quality improvement, efficient operations and network performance."

About DataLink Software

DataLink Software (DataLink) is a healthcare technology company that empowers better health by enabling payers, providers and care partners with real-time data aggregation, EHR connectivity and dynamic dashboards and reporting. DataLink's intelligent, data-driven solutions drive value by reducing the cost of care, improving quality scores, ensuring risk adjustment accuracy and simplifying healthcare navigation. Visit https://datalinksoftware.com/

HEDIS® is a registered trademark of the National Committee for Quality Assurance (NCQA).
The NCQA HEDIS Health Plan Certified Measures
? seal is a service mark of NCQA.


These press releases may also interest you

at 07:10
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent...

at 07:10
IMV Inc. , a clinical-stage biopharmaceutical company (the "Company" or "IMV"), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company's business and clinical operations amid...

at 07:05
LifeMax Laboratories, Inc. ("LifeMax"), a private company focused on treating orphan diseases that have few or no therapeutic options, today announced the formation of AmMax Bio, Inc. ("AmMax") and an exclusive worldwide license from Amgen for the...

at 07:05
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide...

at 07:05
ElevateBio, LLC, a Cambridge-based creator and operator of a portfolio of innovative cell and gene therapy companies, today announced it has closed a $170-million Series B financing that will support and accelerate the company's next phase of growth....

at 07:05
Generation Bio and Vir Biotechnology today announced a collaborative research agreement to explore the potential for Generation Bio's non-viral gene therapy platform to extend the impact and reach of Vir's current or future human monoclonal...



News published on 27 february 2020 at 10:05 and distributed by: